Tyme Technologies, Inc.
|Number of Estimates|
Tyme Technologies, Inc. is a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in New York, NY.
Market Cap: 123 Million
Primary Exchange: NASDAQ
Shares Outstanding: 123 Million
Float: 53.9 Million
Sector: Health Technology
Industry: Pharmaceuticals: Major
Longest drawdown: 2554 trading days
From: 2015-12-30 To: 2020-04-03
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|